BTIG Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5

8-K filing — Neuronetics, Inc. (STIM)

Filed: 2026-08-17 AccNo: 0001193125-26-354051 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

BTIG Maintains Buy on Neuronetics, Raises Price Target to $6

BTIG analyst Sam Eiber maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings

Neuronetics shares are trading higher after the company reported better-than-expected Q2 financial results.